Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Mazdutide

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Innovent · Phase 2 · Completed · Enrollment 179

NCT06124807

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
3/6 Milligrams (mg) Mazdutiden/rn/rn/rn/r
10 mg Mazdutiden/rn/rn/rn/r
16 mg Mazdutiden/rn/rn/rn/r
Placebon/rn/rn/rn/r
3/6 mg Mazdutiden/rn/rn/rn/r

Not shown

  • 3/6 Milligrams (mg) Mazdutide: endpoint not reported
  • 10 mg Mazdutide: endpoint not reported
  • 16 mg Mazdutide: endpoint not reported
  • Placebo: endpoint not reported
  • 3/6 mg Mazdutide: endpoint not reported